SIADH as an Underrecognized Manifestation of Porphyria-like Crises in Hereditary Tyrosinemia Type 1: Clinical and Pathophysiological Insights. [PDF]
Saraceno E +8 more
europepmc +1 more source
Variants in GSTZ1 Gene Underlying Maleylacetoacetate Isomerase Deficiency: Characterization of Two New Individuals and Literature Review. [PDF]
Barretta F +13 more
europepmc +1 more source
Untargeted Metabolomics Reveals Metabolic Reprogramming Linked to HCC Risk in Late Diagnosed Tyrosinemia Type 1. [PDF]
Sidorina A +10 more
europepmc +1 more source
Tyrosinemia type I (TYR I) is caused by autosomal recessive fumarylacetoacetate hydrolase deficiency and is characterized by development of severe liver disease in infancy and neurologic crises.
core
Comment on Dijkstra et al. A False-Negative Newborn Screen for Tyrosinemia Type 1-Need for Re-Evaluation of Newborn Screening with Succinylacetone. Int. J. Neonatal Screen. 2023, 9, 66. [PDF]
Bouva MJ, Maase RE, van Elburg RM.
europepmc +1 more source
A novel acquired resistance mechanism to 5-aminolevulinic acid-mediated photodynamic therapy with ABCG2 inhibition. [PDF]
Chandratre S, Olsen J, Chen B.
europepmc +1 more source
Discovery of newborn Wilson disease biomarkers via integrated next-generation sequencing and untargeted metabolomics. [PDF]
Guan X +9 more
europepmc +1 more source
Correction: Integration of metabolomics and transcriptomics provides insights into the molecular mechanism of temporomandibular joint osteoarthritis. [PDF]
Tuerxun P, Ng T, Zhao K, Zhu P.
europepmc +1 more source
Clinical Spectrum of Hereditary Tyrosinemia Type 1 in a Cohort of Pakistani Children. [PDF]
Khan SA +5 more
europepmc +1 more source
In vivo dissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1. [PDF]
Rivest JF +10 more
europepmc +1 more source

